BI
SLN

BVF Inc’s Silence Therapeutics SLN Stock Holding History

BVF Inc’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,508,416
Closed -$26.2M – 68
2023
Q4 		$26.2M Hold
1,508,416
– – 0.66% 34
2023
Q3 		$14.8M Hold
1,508,416
– – 0.4% 37
2023
Q2 		$8.3M Hold
1,508,416
– – 0.23% 46
2023
Q1 		$9.35M Hold
1,508,416
– – 0.34% 51
2022
Q4 		$23M Hold
1,508,416
– – 0.97% 32
2022
Q3 		$14.9M Buy
1,508,416
+841,750
+126% +$8.86M 0.62% 48
2022
Q2 		$7.9M Hold
666,666
– – 0.38% 54
2022
Q1 		$12.7M Hold
666,666
– – 0.51% 52
2021
Q4 		$15.6M Hold
666,666
– – 0.57% 45
2021
Q3 		$14.4M Hold
666,666
– – 0.56% 48
2021
Q2 		$17M Hold
666,666
– – 0.64% 42
2021
Q1 		$15.8M Buy
+666,666
New +$16.2M 0.59% 38

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
LOAME
Lombard Odier Asset Management (Europe) London, United Kingdom $1.85B AUM 27.05% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

BVF Inc's SLN Position: Q1 2024 in Review

BVF Inc sold out of Silence Therapeutics (SLN) in Q1 2024, closing a stake of 1,508,416 shares — an estimated $26.2M sold.

BVF Inc first reported a position in SLN in Q1 2021 and held it in 12 quarters. The position peaked at $26.2M in Q4 2023. 64 funds tracked by Wall St. Rank hold SLN as of Q1 2024.

  • BVF Inc reported no remaining Silence Therapeutics position as of Q1 2024 after selling out during the quarter.
  • BVF Inc sold 1,508,416 Silence Therapeutics shares in Q1 2024, an estimated $26.2M.
  • BVF Inc first reported a position in Silence Therapeutics in Q1 2021 and held it in 12 quarters.
  • BVF Inc's Silence Therapeutics position peaked at $26.2M in Q4 2023.
  • 64 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2024.

Based on BVF Inc's 13F filing for Q1 2024, filed 15 May 2024.